Daniel Sherbenou, MD, PhD,  is an Associate Professor of Medicine at the University of Colorado, where he is the Director of the Plasma Cell Disorder Program. His professional life is dedicated to treatment and research of multiple myeloma, with a focus on the development of improved treatment approaches. In clinical care, he takes pride in empowering patients with the care team, tools and knowledge to fight their disease and live their best life. As a faculty member in Hematology, Dr. Sherbenou oversees a translational research laboratory group focused on personalized medicine, drug development and understanding how drug resistance occurs and what approaches can be taken to combat it.